ASCO Value Framework Could Inform Clinical Pathways, Payers Say
Aetna’s Kolodziej and Anthem’s Malin discuss how the American Society for Clinical Oncology’s framework for valuing cancer drugs might influence payer decision-making and drug access.
You may also be interested in...
Over the last two years, UnitedHealthcare and Aetna have launched cancer pathway programs with the overall goals of standardizing and improving care and lowering cost. Drug therapy is a key focus.
The most detailed US reporting requirements regarding prescription drug costs and coverage will target medicines reimbursed under the retail pharmacy benefit.
US government is paying Merck & Co. around $181 more per course of treatment for its oral antiviral for COVID-19, molnupiravir, than it is to Pfizer for its competing drug.